Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fenebrutinib (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms FENopta
Sponsors Roche

Most Recent Events

19 Aug 2026 Planned End Date changed from 30 Dec 2026 to 26 Dec 2026.
24 Sep 2025 According to a Genentech media release, data from this study will be presented as on oral presentation at the at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain (September 24-26 )
24 Sep 2025 Results presented in the Genentech Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com